Damora Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
DMRA$24.15+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets · (unaudited) | ||
| Current assets | ||
| Cash and cash equivalents | $532,899 | $257,624 |
| Prepaid expenses and other current assets | 2,509 | 2,799 |
| Total current assets | 535,408 | 260,423 |
| Other assets, noncurrent | 34 | 104 |
| Total assets | $535,442 | $260,527 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $819 | $444 |
| Accrued expenses and other current liabilities | 5,997 | 2,401 |
| Paramora warrant obligation | 4,984 | — |
| Related party accounts payable and other current liabilities | 12,012 | 17,221 |
| Total current liabilities | 23,812 | 20,066 |
| Other liabilities, noncurrent | 27 | 81 |
| Total liabilities | $23,839 | $20,147 |
| Commitments and contingencies (Note 11) | ||
| Mezzanine equity | ||
| Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; 159 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | 1,341 | 1,341 |
| Stockholders’ equity | ||
| Series B non-voting convertible preferred stock, par value of $0.00001 per share; 16,366 shares authorized at March 31, 2026 and December 31, 2025; 16,366 shares issued and outstanding as of March 31, 20216 and December 31, 2025 | 117,621 | 117,621 |
| Series C non-voting convertible preferred stock, par value of $0.00001 per share; 43,882 shares authorized at March 31, 2026 and December 31, 2025; 1,877 and 43,882 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | 13,490 | 297,291 |
| Common stock, par value of $0.00001 per share; 500,000,000 shares authorized at March 31, 2026 and 300,000,000 shares authorized at December 31, 2025; 60,303,212 and 1,597,321 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 1 | — |
| Additional paid-in capital | 893,542 | 310,688 |
| Accumulated deficit | (515,146) | (487,363) |
| Accumulated other comprehensive income | 754 | 802 |
| Total stockholders’ equity | 511,603 | 240,380 |
| Total liabilities and stockholders’ equity | $535,442 | $260,527 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.